Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II darolutamide plus goserelin in androgen receptor-expressing salivary gland carcinoma
KCT0007110Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2022
- Modality
- Small Molecules, Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darolutamide and goserelin in salivary gland cancer (SGC), sponsored by Bayer. Primary endpoint: Progression-free survival. Started Sep 2022; status: completed.
02
Drugs
darolutamidegoserelin
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on KCT0007110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007110.